IRLAB’s Pioneering Phase IIb Study with Pirepemat – React-PD – Provides New Insights in Specific Parkinson’s Patient Population and Enables a Data Driven Prediction of Study Timelines

By / 06/02/2024

IRLAB Therapeutics Gothenburg, Sweden, February 6, 2024 – IRLAB Therapeutics AB is a company discovering and developing novel treatments for Parkinson’s disease.